Cabazitaxel with Abiraterone versus Abiraterone Alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial

Protocol No
ECOG-EA8153-CHAARTED2
Principal Investigator
Kathryn Bylow
Phase
II
Summary
The purpose of this research study is to compare any good or bad effects of using the chemotherapy drug cabazitaxel (also known as Jevtana®) with the usual approach of the hormone based therapy abiraterone acetate (also known as Zytiga®) in combination with prednisone on patients with advanced prostate cancer that have already undergone treatment with hormone therapy and the chemotherapy drug docetaxel. In this research study, you will get either the standard of care combination of abiraterone acetate and prednisone, or you will get abiraterone acetate and prednisone in combination with the chemotherapy drug cabazitaxel. To be better, the study drug should delay the development of resistance to abiraterone acetate and prednisone by 6 months or more compared to the usual approach. There will be about 210 people taking part in this research study.
Description
The CHAARTED2 Trial HSPC Previously Treated With Docetaxel & ADT
Participating Institutions
Froedtert Hospital
Community Memorial Hospital
St. Joseph's Hospital - West Bend
Status
OPEN TO ACCRUAL
Share This: